arch42

EN_01447234_0435

30,00 EUR Private use
Making print for private purpose, storage in computer memory, no distribution rights.
40,00 EUR Internet - private use
Strictly for editorial, single use on a personal (nonprofit) web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
75,00 EUR Internet commercial use
Strictly for editorial, single use on a commercial web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
90,00 EUR Print use
Strictly for editorial, single use, inside of newspaper, magazine, book (including digital version), one edition, one single country. Not for resale.

Gross prices

special instructions

SEPT. 6, 2020, PHOTO

caption

An employee answers questions from the public near samples of a COVID-19 vaccine produced by Sinopharm subsidiary CNBG are displayed during a trade fair in Beijing on Sept. 6, 2020. CNBG has injected 350,000 people outside its clinical trials for COVID-19 vaccine, which have about 40,000 people enrolled. It's a highly unusual move that raises ethical and safety questions, as companies and governments worldwide race to develop a vaccine that will stop the spread of the new coronavirus. (AP Photo/Ng Han Guan)

headline arch42

created date 2020-09-06

credit AP/Associated Press/East News

source Associated Press

byline AP

original transmission reference 20269508058865

weight 4,44MB

size 34cm x 23cm by 300dpi

keywords - Show

000, 2020, 350, 40, 6, A, ABOUT, AN, AND, ANSWERS, AP, ARE, AS, BEIJING, BY, CLINICAL, CNBG, COMPANIES, CORONAVIRUS, COVID-19, DEVELOP, DISPLAYED, DURING, EMPLOYEE, ENROLLED, ETHICAL, FAIR, FOR, FROM, GOVERNMENTS, GUAN, HAN, HAS, HAVE, HIGHLY, IN, INJECTED, IT, ITS, MOVE, NEAR, NEW, NG, OF, ON, OUTSIDE, PEOPLE, PRODUCED, PUBLIC, QUESTIONS, RACE, RAISES, SAFETY, SAMPLES, SEPT, SINOPHARM, SPREAD, STOP, SUBSIDIARY, THAT, THE, TO, TRADE, TRIALS, UNUSUAL, VACCINE, WHICH, WILL, WORLDWIDE,